MCL1 and cancer: Accordingly, small-molecule inhibitors (BH3 mimetics) of MCL-1L imitating the function of pro-apoptotic BH3-only proteins demonstrated activity in different types of cancer when used alone or in combinations with other anti-cancer drugs [10–13], and they are under ongoing evaluations in clinical trials e.g., NCT04702425 and NCT03013998.